SCHEMBL2760176

SCHEMBL2760176

Cc1ccc(CN/C(=N\C#N)N2CCOCC2)o1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.36
MAPT P10636 7/20 0.36
LMNA P02545 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
CYP3A4 P08684 2/20 0.35
POLB P06746 1/20 0.35
SCN9A Q15858 1/20 0.34
CHRM2 P08172 1/20 0.34
PKM P14618 4/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
KDM4E B2RXH2 2/20 0.34
HTT P42858 1/20 0.34
RECQL P46063 1/20 0.34
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2736382 0.86 ALDH1A1 (0.35) ALDH1A1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2760089 0.74 HTT (0.50) ALDH1A1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL13701373 0.71 CTSS (0.41) ALDH1A1MAPTLMNASMN1; SMN2MEN1
SCHEMBL12619275 0.71 CTSS (0.38) MAPTSMN1; SMN2KDM4EHTT
SCHEMBL13617149 0.69 HTT (0.34) MAPTSMN1; SMN2KDM4EHTTHSD17B10
SCHEMBL14996224 0.69 CTSS (0.40) ALDH1A1MAPTSMN1; SMN2PKMHTT
SCHEMBL2736388 0.68 CTSS (0.36) ALDH1A1MAPTLMNASMN1; SMN2PKM
SCHEMBL11989259 0.67 CTSS (0.34) MEN1KMT2APOLBPKMHTT
SCHEMBL12652971 0.67 POLB (0.40) MEN1KMT2APOLBPKMHTT
SCHEMBL14517021 0.65 MAPK1 (0.52) ALDH1A1LMNASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088766-B2 Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors ARRAY BIOPHARMA INC. (US) 2012-01-03 US disclosed
US-7488823-B2 Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors ARRAY BIOPHARMA, INC. (US) 2009-02-10 US disclosed
US-20090012290-A1 CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS ARRAY BIOPHARMA, INC. (US) 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012290-A1 CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS ERBB2, GRB2, EGFR ALDH1A1 4357/4885MAPT 4820/4885LMNA 3951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.